Handai Candesartan anti-atherogenesis Trial on diabetic patients with hypertension using CT examination

UMIN ID: UMIN000001453

Registered date:01/04/2010

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Type 2 diabetic patients with hypertension
• Date of first enrollment: 2008/04/01
• Target sample size: 100
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Each subject has already received orally Candesartan (4 mg or 8 mg once daily). Same dose of candesrtan will be administered for a year.
Each subject has already received orally Candesartan (4 mg or 8 mg once daily). When necessary, high dose of candesrtan (up to 12 mg once daily) will be administered for a year. The targets of blood pressure control are as follow; systolic <130 mmHg, diastolic <80 mmHg.

Outcome(s)

• Primary Outcome: Changes of metabolic parameters, oxidative stress markers, adipocytokines, visceral fat areas, quality and quantity of coronary plaque, and carotid intima-media complex thickness (IMT), at the completion of treatment form baseline

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1)Contraindications of candesartan 2)Contraindications of contrast agent

Related Information

• Primary Sponsor: Department of Metabolic Medicine, Graduate School of Medicine, Osaka University
• Source(s) of Monetary Support: Department of Metabolic Medicine, Graduate School of Medicine, Osaka University